Evicenter
Shingrix (Zoster Vaccine Recombinant, Adjuvanted) in Herpes zoster prevention
Manufacturer
GlaxoSmithKline Biologicals; GlaxoSmithKline
Prescribing information
Shingrix (opens in a new tab)
Questions
47
Last updated

All questions

Indication: Shingrix (Zoster Vaccine Recombinant, Adjuvanted) in herpes zoster prevention

5 questions · 5 sources

Indication

Is Shingrix approved for immunocompromised adults 18 and older?

Applies to Prevention of herpes zoster (shingles) in adults aged 18 years and older who are or will be at increased risk of herpes zoster due to immunodeficiency or immunosuppression caused by known disease or therapy

Is Shingrix indicated to prevent postherpetic neuralgia in adults 50 and older?

Applies to Prevention of herpes zoster (shingles) in adults aged 50 years and older

Eligibility

Shingrix: which adults 50 and older are at higher risk of shingles?

Applies to Prevention of herpes zoster (shingles) in adults aged 50 years and older

“Patients ≥50 years old may have additional risk factors: certain comorbidities and psychological stress have been associated with increased risk of shingles4,† DIABETES 24 % INCREASED RISK in patients with DIABETES vs without 32 studies, pooled effect estimate: RR: 1.24 (95% CI: 1.14-1.35) CHRONIC KIDNEY DISEASE 29 % INCREASED RISK in patients with CHRONIC KIDNEY DISEASE vs without 18 studies, pooled effect estimate: RR: 1.29 (95% CI: 1.10-1.51) CARDIOVASCULAR CONDITIONS 34 % INCREASED RISK in patients with CARDIOVASCULAR CONDITIONS‡ vs without 16 studies, pooled effect estimate: RR: 1.34 (95% CI: 1.17-1.54) PSYCHOLOGICAL STRESS 47 % INCREASED RISK in patients with PSYCHOLOGICAL STRESS§ vs without 8 studies, pooled effect estimate: RR: 1.47 (95% CI: 1.03-2.10) † Data from a meta-analysis assessing risk factors for HZ. The analysis included a total study population of 198,751,846 individuals, with 3,768,691 HZ cases across 88 studies (68 cohort and 20 case-control studies) from 1966 to 2019. The populations in these studies ranged from people aged 3 months to 104 years old.‖ Eighteen risk factors were identified in the meta-analysis, note not all are presented here. Limitations included the following: most studies were observational and had a higher likelihood of bias; the majority of studies used administrative data, which is subject to miscoding, errors, and can vary between practitioners; finally, heterogeneity was high across studies. This list is not exhaustive and may not present all conditions associated with an increased risk of HZ.4 ‡ Cardiovascular conditions included in each individual study in the meta-analysis varied by study and included heart disease, heart failure, hypertension, hyperlipidemia, stroke, atrial fibrillation/flutter, and other cardiovascular disease.4 § The methodology used to define psychological stress varied greatly across studies and included patient questionnaires and major life events (either self-reported or captured on medical record, eg, death of a spouse or diagnosis of major medical event).4 ‖ SHINGRIX is a vaccine indicated for prevention of HZ (shingles) in adults aged 50 years and older.3 Cl=confidence interval; COPD=chronic obstructive pulmonary disease; RR=relative risk; VZV=varicella zoster virus.” (opens the source at this quote in a new tab)

Note: The relative risks are pooled estimates from a meta-analysis of mostly observational studies (Marra et al., 2020); the footnote lists its limitations. The meta-analysis included people of all ages, so the estimates are not specific to adults 50 and older.

Shingrix: what is the lifetime risk of shingles?

Applies to Prevention of herpes zoster (shingles) in adults aged 50 years and older

Note: The 1 in 3 figure is a lifetime risk for people in general, cited on the Support for Nurses page of the Shingrix HCP site to a CDC clinical overview of shingles.

Shingrix: which immunocompromised adults are at increased risk of shingles?

Applies to Prevention of herpes zoster (shingles) in adults aged 18 years and older who are or will be at increased risk of herpes zoster due to immunodeficiency or immunosuppression caused by known disease or therapy

Note: The first four passages are from patient profiles (not actual patients) on the Patient Profiles page of the immunocompromised section of the Shingrix HCP site; the last is from its Patient Counseling page.